Fosun Pharmaceuticals (600196.SH): HLX22 combined with injectable HLX87 approved for clinical trials

Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) announced that recently, the company's holding subsidiary Shanghai Fuhong Hanlin Biotechnology Co., Ltd. and its holding subsidiary (hereinafter collectively referred to as “Fuhong Hanlin”) received approval from the State Drug Administration for HLX22 (that is, recombinant humanized anti-HER2 monoclonal antibody injection) and HLX87 (i.e. targeted HER2 antibody conjugate drug) to carry out the following clinical trials in China: (1) Phase II/III clinical trials for first-line treatment of HER2-positive breast cancer (BC); 2) Phase II/III clinical trial for HER2 positive breast cancer neoadjuvant therapy (BC neo). Fu Hong Hanlin plans to carry out the above related clinical studies in China after conditions are met.